BiotechTube
CellTivity Scientific

CellTivity Scientific

Lyon, France· Est.
celltivity.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

CellTivity Scientific, founded in 2015 and based in Lyon, France, with significant US operations, is a commercial-stage diagnostics company in the cell therapy and regenerative medicine sectors. Its core technology, the Van Gogh™ Dynamic Cell Imaging platform, visualizes cellular metabolic activity in real-time to guide proceduralists during biopsies, with the goal of improving diagnostic yield and sample adequacy for next-generation sequencing. The company is targeting the lung cancer diagnosis market first, with endorsements from US-based interventional pulmonologists, and appears to be generating early revenue from the commercial rollout of its Van Gogh system.

OncologyLung Cancer

Technology Platform

Van Gogh™ Dynamic Cell Imaging (DCI) platform that produces real-time metabolic 'heat maps' of biopsy samples to visualize atypical cellular metabolism for point-of-care adequacy assessment.

Funding History

2
Total raised:$4M
Seed$3.2M
Grant$800K

Opportunities

The primary opportunity lies in reducing the high rate of non-diagnostic cancer biopsies, which can accelerate time-to-treatment and lower healthcare costs.
The platform-agnostic nature of its metabolic imaging technology allows for potential expansion into other solid tumor types and even into cell therapy manufacturing quality control.

Risk Factors

Key risks include slow adoption by clinicians accustomed to existing workflows, challenges in securing favorable insurance reimbursement, and competition from both traditional methods (ROSE) and emerging digital pathology solutions.
As a private company, execution risk in scaling commercial operations is also significant.

Competitive Landscape

CellTivity competes with traditional Rapid On-Site Evaluation (ROSE) services performed by cytotechnologists and with emerging digital pathology tools. Its main differentiation is the real-time, point-of-care visualization of cellular metabolism rather than static morphology, positioning it as an immediate procedural aid rather than a remote diagnostic tool.

More companies in Diagnostics & Precision Medicine →More companies in France →